734-936-8000 - Service Desk | Request Support

Anticoagulation Management - 2020

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials
Posttest
Evaluation
Release Date: Wed, 1/1/20
Termination Date: Thu, 12/31/20
Credits: 2
Description: Anticoagulants are used for many reasons, including the treatment or prevention of venous thromboembolism and the prevention of stroke in patients with atrial fibrillation. Managing anticoagulants effectively is very important to help maximize efficacy while minimizing bleeding risk. This CME activity helps clinicians understand key elements of anticoagulation management around areas such as determining risk, anticoagulant selection and initiation, and long-term management. The educational material provides information on the most recent national and international guidelines, summaries of FDA approved oral anticoagulants, useful clinical protocols, and decision making algorithms.
Educational Objectives: Participants in this CME activity will have a better understanding of anticoagulation and will be able to more safely and effectively evaluate the need for anticoagulation, initiate anticoagulation, and handle long-term management situations according to evidence-based guidelines and protocols.
Target Audience: This self-study activity is appropriate for any clinician involved with anticoagulation initiation or long-term management.
Accreditation Information: The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Original Release Date: April 2015
Termination Date: March 2021

Continued availability of CME credit for this activity depends on a thorough review of its content every three years. This activity was last reviewed for currency and accuracy in April 2018, and availability of CME credit continued.
Additional Info: Authors:
Geoff Barnes, MD; University of Michigan, Cardiology
Jim Froehlich, MD; University of Michigan, Cardiology
Brian Haymart, RN; University of Michigan, Cardiology
Tina Alexandris-Souphis, RN; University of Michigan, Cardiology
Eva Kline-Rogers, RN; University of Michigan, Cardiology
Kim Eagle, MD; University of Michigan, Cardiology
Scott Kaatz, DO; Hurley Medical Center, Internal Medicine
Jay Kozlowski, MD; Huron Valley Sinai, Cardiology
Gregory Kroll, MD; Henry Ford Hospital, Internal Medicine
Steve Almany, MD; William Beaumont Hospital, Cardiology
Brian Kurtz, PharmD; University of Michigan, Cardiology
Elizabeth Renner, PharmD; University of Michigan, Cardiology
Vinay Shah, MD; Henry Ford Hospital, Internal Medicine
Syed Ahsan, MD; Henry Ford Hospital, Internal Medicine

Author Disclosures
Geoff Barnes, MD
Consultant: Portolal
Grant/Research Support: Blue Cross/Blue Shield of Michigan, Bristol Myer Squibb/Pfizer

Jim Froehlich, MD
Consultant: Sanofi-Aventis, Ortho-McNeil, Merck
Grant Support: Sanofi-Aventis, Blue Cross/Blue Shield of Michigan, Mardigian Foundation, Fibromuscular Disease Society of America

Eva Kline-Rogers, RN
Consultant: Janssen, American College of Cardiology
Board membership: AC Forum

Scott Kaatz, DO
Consultant: Boehringer-Ingelheim, Janssen, Daiichi Sankyo, Bristol Myer Squibb/Pfizer
Speaker honorarium: Janssen, Boehringer-Ingelheim, Bristol Myer Squibb/Pfizer, CSL Behring

Vinay Shah, MD
Consultant: Bristol Myer Squibb
Grant/Research Support: Bristol Myer Squibb/Pfizer, Merck/Boehringer-Ingelheim

Syed Ahsan, MD
Grant/Research Support: Pfizer, Bristol Myers Squib, NIH

There are no other relevant financial relationships to disclose for this CME activity.

Credits available:

AMA PRA Category 1: 2.00
Participation: 2.00